Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Trial of Standard vs. Hypofractionated Accelerated Radiotherapy for Progression in Limited-Stage Small Cell Lung Cancer (SHARP-SCLC)

NCT07920549 is registered in ClinicalTrials.gov with London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07920549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Trial of Standard vs. Hypofractionated Accelerated Radiotherapy for Progression in Limited-Stage Small Cell Lung Cancer (SHARP-SCLC)
Lead sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
September 30, 2036
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

limited stage small-cell lung cancer

Arms

As registered; 2 arms.

  • Standard Thoracic Radiotherapy Active comparatorChemotherapy, Radiation Therapy
  • Hypofractionated Accelerated Thoracic Radiotherapy ExperimentalChemotherapy, Hypofractionated Radiation Therapy

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Progression-free survival From randomization to disease progression or death, assessed for up to 60 months.

    Progression-free survival (PFS) is defined as the time from randomization to the first occurrence of disease progression or death from any cause, whichever occurs first. Disease progression will be assessed using RECIST version 1.1 criteria. Participants without documented progression or death will be censored at the date of their last adequate disease assessment.

Lead sponsor's other trials

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, most recent start first.

Similar trials

Same condition (Small Cell Lung Carcinoma) and phase, most recent start first.